GLP-3R

GLP-3R is a research peptide studied as a triple agonist at the GLP-1, GIP, and glucagon receptors. Research examines whether engaging all three receptors affects metabolic regulation differently from dual or single agonists. It has been evaluated in randomized clinical trials for obesity, type 2 diabetes, and metabolic dysfunction-associated steatotic liver disease, and is sold by CoreX for laboratory research use only.

Research investigates GLP-3R across three receptors. GLP-1 and GIP receptor activity is associated with glucose-dependent insulin signaling and satiety, while glucagon receptor activity is associated with energy expenditure. Studies explore whether the glucagon component adds an expenditure effect alongside appetite signaling, which is the main feature distinguishing it from dual GLP-1/GIP agonists.

Published work includes a phase 2 randomized trial in obesity, a phase 2a randomized trial in metabolic dysfunction-associated steatotic liver disease, and a double-blind randomized phase 3 trial in people with type 2 diabetes and inadequate glycemic control on diet and exercise. Registrational trials have also been designed to examine obesity, obstructive sleep apnea, and knee osteoarthritis.

Safety outcomes were assessed in the phase 2 and phase 3 randomized trials, but the specific adverse event profile is not summarized on this page. Long-term human safety data remain limited, and larger registrational trials are ongoing. No regulatory approval has been reported, and GLP-3R supplied by CoreX is intended for laboratory research use only.

Research protocols have used 500 to 4,000 mcg per administration by subcutaneous route, once weekly (morning, fasted), stepping up from 1 mg to 4 mg by week 9. The reported cycle continued until target weight loss, and a long-term non-weight-loss model used 1 mg weekly. Each CoreX order ships with a protocol guide for laboratory reference.